PCM
FLXN

Perkins Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Perkins Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,800
Closed -$89K – 110
2021
Q2 		$89K Buy
+10,800
New +$91.8K 0.05% 99
2018
Q3 		– Sell
-41,800
Closed -$1.08M – 141
2018
Q2 		$1.08M Buy
41,800
+1,250
+3% +$32.4K 0.77% 44
2018
Q1 		$909K Sell
40,550
-12,950
-24% -$316K 0.82% 42
2017
Q4 		$1.34M Buy
+53,500
New +$1.31M 1.29% 20

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perkins Capital Management's FLXN Position: Q3 2021 in Review

Perkins Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 10,800 shares — an estimated $89K sold.

Perkins Capital Management first reported a position in FLXN in Q4 2017 and held it in 4 quarters. The position peaked at $1.34M in Q4 2017. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

  • Perkins Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Perkins Capital Management sold 10,800 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $89K.
  • Perkins Capital Management first reported a position in Flexion Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
  • Perkins Capital Management's Flexion Therapeutics, Inc. position peaked at $1.34M in Q4 2017.
  • 145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Perkins Capital Management's 13F filing for Q3 2021, filed 25 Oct 2021.